Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00933933 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Diagnostic HIV Ag/Ab Combo Assay
A Phase 3 study, sponsored by Abbott Diagnostics Division.
- Completed
- Registry status
- Phase 3
- Development phase
- 635
- Enrollment target
NCT00933933: Completed Phase 3 study, sponsored by Abbott Diagnostics Division.
NCT00933933 is a Phase 3 study that has completed, run by Abbott Diagnostics Division. The registered enrollment target is 635 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00933933, a Phase 3 study, has completed, sponsored by Abbott Diagnostics Division.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 635 participants
- Enrollment target
Study Summary
To test blood specimens using a new investigational test that detects antigen and antibody to human immunodeficiency virus (HIV). Results will be compared to an approved HIV antibody test and supplemental testing performed to determine HIV status.
Interventions
- DEVICE ARCHITECT HIV Ag/Ab Combo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 635 participants |
| Start Date | 2009-06 |
| Est. Completion | 2009-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00933933
The ClinicalTrials.gov registry entry for NCT00933933 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 635 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott Diagnostics Division, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ARCHITECT HIV Ag/Ab Combo is the first listed.
NCT00933933 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00933933 about?
NCT00933933 is a clinical study titled "Evaluation of Diagnostic HIV Ag/Ab Combo Assay". To test blood specimens using a new investigational test that detects antigen and antibody to human immunodeficiency virus (HIV). Results will be compared to an approved HIV antibody test and supplemental testing performed to determine HIV status.
What is the current status of trial NCT00933933?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 635 participants. The study started on 2009-06. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00933933?
The interventions under investigation include: ARCHITECT HIV Ag/Ab Combo (DEVICE).
Who is sponsoring clinical trial NCT00933933?
This trial is sponsored by Abbott Diagnostics Division, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.